<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url><loc>https://peptide.global/story/ribupatide-weight-loss-trial-china</loc><news:news><news:publication><news:name>Peptide Global</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17T08:25:00.000Z</news:publication_date><news:title>Ribupatide weight loss trial in China puts Hengrui obesity filing in focus</news:title></news:news></url>
  <url><loc>https://peptide.global/story/ozempic-jamaica-cleared-distribution</loc><news:news><news:publication><news:name>Peptide Global</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17T07:41:00.000Z</news:publication_date><news:title>Ozempic in Jamaica cleared for distribution as Tufton promises cheaper generics</news:title></news:news></url>
  <url><loc>https://peptide.global/story/foundayo-approval-australia-glp-1-pill</loc><news:news><news:publication><news:name>Peptide Global</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17T07:20:00.000Z</news:publication_date><news:title>Foundayo approval in Australia brings a second GLP 1 pill to private scripts</news:title></news:news></url>
  <url><loc>https://peptide.global/story/wegovy-generic-korea-united-pharm</loc><news:news><news:publication><news:name>Peptide Global</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17T06:45:00.000Z</news:publication_date><news:title>Wegovy generic in Korea moves toward a 2028 launch as Korea United Pharm plans a first trial</news:title></news:news></url>
  <url><loc>https://peptide.global/story/efinopegdutide-mash-hanmi-valuation</loc><news:news><news:publication><news:name>Peptide Global</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-11-17T06:02:00.000Z</news:publication_date><news:title>Efinopegdutide MASH data lift Hanmi valuations as MSD weighs Phase 3</news:title></news:news></url>
</urlset>